Menu di pagina
- IRE Research and Technology
- IRE Competitive Grants
- PerfeTTO
- INNOVA
- Immune Metabolism Dysregulation and Efficacy of Anti-PD-1/PD-L1 Agents in Non-Small Cell Lung Cancer (NSCLC)
- Artificial Intelligence and Machine Learning Based Risk Prediction Model for Improving Endometrial Cancer Clinical Management
- Low-Intensity Extracorporeal Shockwave Therapy on Penile Rehabilitation after robot-assisted surgical treatment of genitourinary cancers
- Deciphering KEAPness for Improved Immunotherapy Prediction and Treatment
- MiRNA-based therapeutic approach to fight triple negative breast cancer
- Beyond the creation of a living biobank: dissecting the transcriptomic landscape of Gastro-entero-pancreatic neuroendocrine neoplasms
- Multidimensional assessment of virus-associated head and neck cancer patients for the discovery of predictive biomarkers to guide clinical intervention
- TArgeting drug resistant melanoma with miCroRNAs delivered by Lipid NanoparTICles (TACTIC)
- Addressing liver fibrosis prevention and treatment: an unbiased query on the hepatic microenvironment with a perspective targeting of the pro-fibrotic kinase HIPK2
- Analyses of HPV and host body fluid biomarkers as non-invasive strategy for detection of head and neck cancer relapse
- Deciphering Biology of R/R DLBCL Subtypes: miRNA Biomarkers for Optimizing Treatment and Survival
- Clinically approved drugs targeting pyruvate kinase M2: a drug repurposing pathway to move forward the treatment of glioblastoma
- Developing a Biobank Network Among Major Sarcoma Treatment Centers to Improve Biomedical Research
- Identification and Validation of Prognostic and Predictive Biomarkers, Including E3 Ubiquitin Ligases and MicroRNA Signature, for the Development of New Immunotherapeutic Approaches in Glioma
- Heal Italia
- D3 4 Health
- TRIglIFO2 project
- Poc MIMIT Project
- The PROMlSE project
- The 4Immunogenomics project
- Project ERBB2
- Project NANO-COVID-TEST
- Progetto DOMINO – Lazio Innova
- Project GEMMA – Lazio Innova
- Project COMETA
- Exploring the role of Bcl-2 family in the immune surveillance of melanoma: from mechanisms to therapeutic perspectives
- Exploring how endothelin-1/PIEZO axis intersects mechanical forces to fuel PARP inhibitor resistance in ovarian cancer
The PROMlSE project
A new PROtocol for the Management of syndromic pedlatric conditionS involving Epileptic behavior (PROMlSE)
Project description
The PROMlSE project will consist of 3 main actions necessary to optimize the management of the "health condition" of complex patients.
The first action (Action 1) will concern the execution of Whole Exome Sequencing (WES) on patients' blood samples in order to evaluate genetic mutations with an impact on the pathology present (epilepsy) or secondary mutations that can cause further hereditary genetic pathologies or tumors, This analysis will aim not only to identify an epileptic condition linked to a genetic syndrome, but also to identify an epileptic condition linked to a genetic syndrome, but to assess the presence of additional variants capable of determining the pathological states in the patient not related to the pathology already present.
The second action (Action 2) will concern the evaluation of two classes of diagnostic/prognostic markers, molecular (miRNA, DNA) and biochemical, able to allow a longitudinal analysis of the clinical manifestations associated with the epileptic condition.
The third action (Action 3) will consist in the creation of brain tissue organoids (from iPSCs from skin fibroblasts) for the creation of a customized tissue model on which to carry out analysis and therapeutic validation activitie.
Purpose
Among the main objectives of the PROMlSE project is the creation of a diagnostic protocol (of which a dossier will be prepared for the Regional Health Service) for paediatric patients to be applied as a standard and having an excellent cost/benefit ratio as well as a high degree of sustainability.
Results
Identification of impactful events;
"Assessment" of impacting events and the identification of metrics to measure their intensity and persistence;
"Intervento" sugli eventi impattanti mediante lo sviluppo di sistemi per l'identificazione di terapie mirate.
Financial Support
PR FESR LAZIO 2021 – 2027
The total is grant of the project is 501.337,95 euro (CUP: F89J23001190007)
The GRANT assigned to IFO-IRE is 66.428,66 euro (codice CUP IFO-IRE: H83C23001910007)
Principal Investigator: Dott. Giovanni Blandino, UOC Ricerca Traslazionale Oncologica IRE
The funding resources are from the public notice "Riposizionamento Competitivo RSl" - Ambito 1 ”Scienze della vita” approved with Determination n. G18823 of 28/12/2022, PR FESR 2021-2027;
Proposal number A0613-2023-078041 del 14/03/2023, approved with Determination n. G15206 of 16/11/2023.
The European Regional Development Fund (ERDF) aims to consolidate economic and social cohesion in the European Union by correcting any disparities that may exist between regions.
Go to the page